<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Most patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are older than 60 years and age-associated morbidities limit the patients' options for curative transplant therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Since the development of conditioning regimens with reduced toxicity, the age limitations for HCT have waned for those patients with good performance status </plain></SENT>
<SENT sid="3" pm="."><plain>This review will discuss the role of HCT for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> based on prognostic features, the optimal timing of HCT, and outcomes based on patient age </plain></SENT>
</text></document>